Mayo Clinic's Hematologic Malignancies Program has a strong tradition of advanced research to improve the diagnosis and treatment of blood cancers.
Researchers at Mayo Clinic have played a key role in developing new drug treatments for multiple myeloma and continue to study new therapies. Mayo researchers developed new classification systems that divide multiple myeloma into high-risk, intermediate-risk and standard-risk categories, and shone light on how a little-understood gene, MMSET, may play a role in multiple myeloma.
Continuing research efforts related to multiple myeloma include:
See a list of publications by Mayo Clinic doctors on multiple myeloma on PubMed, a service of the National Library of Medicine.